New drug cocktail aims to fight tough stomach cancer

NCT ID NCT07584135

Recruiting now Disease control Sponsor: NingBo Junyan Hongshi Biosciences Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This Phase 3 trial tests a new drug called JS107 combined with toripalimab and chemotherapy against a standard treatment for advanced stomach cancer that has a specific marker (CLDN18.2). The study plans to enroll 600 people whose cancer has spread and cannot be removed by surgery. The goal is to see if the new combination helps patients live longer without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS107 (a drug) combined with toripalimab and chemotherapy (oxaliplatin and capecitabine)
What this could lead to: If successful, this could offer a new first-line treatment option for people with a specific type of advanced stomach cancer, potentially improving how long they live without the cancer growing.
What could go wrong: This is an early-stage Phase 3 trial that hasn't started recruiting yet. The new combination may not be more effective than the existing treatment and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.